FDA對MRNA是扶持對NVAX是打壓.是的.澳洲打4種疫苗,副作用有報道.mrna臨床不報道不等於實際心肌炎少.

最後以實際打下來結果看。

https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report/current

Nuvaxovid (Novavax) vaccine

The Nuvaxovid (Novavax) vaccine has been provisionally approved for adults. To 29 May 2022, about 146,300 doses of Nuvaxovid (Novavax) have been administered in Australia. The TGA has received 726 reports of suspected adverse events. We are closely monitoring these reports. The most commonly reported reactions include chest pain, headache, fatigue, paraesthesia and dizziness.

Paraesthesia is an unusual feeling in the skin, such as tingling or a crawling sensation, and has also been reported for other COVID-19 vaccines. It is not known why paraesthesia sometimes occurs after vaccination, but it is thought it may be a stress-related response to immunisation rather than an immune reaction.

We have received a small number of reports of suspected myocarditis and/or pericarditis in people who have received the Nuvaxovid (Novavax) vaccine. After assessing these against a set of internationally accepted criteria, 3 cases were likely to represent myocarditis and 11 were likely to represent pericarditis. We are closely monitoring these reports and investigating whether there is an association between the Nuvaxovid (Novavax) vaccine and myocarditis and pericarditis. We will provide more information on this when the investigation is finalised.

In the AusVaxSafety survey(link is external)， the most commonly reported reactions to Nuvaxovid (Novavax) are fatigue, injection-site reactions and headache. These are expected side effects that were also seen in clinical trials.

 

Comirnaty (Pfizer) and Spikevax (Moderna)

"Myocarditis is a known but very rare side effect of Comirnaty (Pfizer) and Spikevax (Moderna). It is usually temporary, with most people getting better within a few days. Myocarditis is reported in around 1-2 in every 100,000 people who receive Comirnaty (Pfizer) and 2-3 of those who receive Spikevax (Moderna). However, it is more common after the second dose in 12-17 year-old boys (12 cases per 100,000 Comirnaty doses and 20 cases per 100,000 Spikevax doses)

and men under 30 (8 cases per 100,000 Comirnaty doses and 18 cases per 100,000 Spikevax doses)." 

 

 

 

https://www.caus.com/detail/57631

https://med.sina.cn/article_detail_103_1_114427.html